BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37736725)

  • 21. Patients with periodontitis might increase the risk of urologic cancers: a bidirectional two-sample Mendelian randomization study.
    Li B; Lin Y; Yang Y; Wang Z; Shi R; Zheng T; Liao B; Liao G; Huang J
    Int Urol Nephrol; 2024 Apr; 56(4):1243-1251. PubMed ID: 38015384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [De novo urologic tumors in kidney transplant patients].
    Rodríguez Faba O; Breda A; Gausa L; Palou J; Villavicencio H
    Actas Urol Esp; 2015 Mar; 39(2):122-7. PubMed ID: 24996779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study.
    Montella M; Di Maso M; Crispo A; Grimaldi M; Bosetti C; Turati F; Giudice A; Libra M; Serraino D; La Vecchia C; Tambaro R; Cavalcanti E; Ciliberto G; Polesel J
    BMC Cancer; 2015 Oct; 15():720. PubMed ID: 26475132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The associations of metabolic syndrome with incident hypertension, type 2 diabetes mellitus and chronic kidney disease: a cohort study.
    Ding C; Yang Z; Wang S; Sun F; Zhan S
    Endocrine; 2018 May; 60(2):282-291. PubMed ID: 29492904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association Between Metabolic Syndrome and the Risk of Colorectal Cancer Diagnosed Before Age 50 Years According to Tumor Location.
    Jin EH; Han K; Lee DH; Shin CM; Lim JH; Choi YJ; Yoon K
    Gastroenterology; 2022 Sep; 163(3):637-648.e2. PubMed ID: 35643169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic Syndrome Components and the Risk of Colorectal Cancer: A Population-Based Prospective Study in Chinese Men.
    Li X; Chen H; Wang G; Feng X; Lyu Z; Wei L; Wen Y; Chen S; Wu S; Hang D; Dai M; Li N; He J
    Front Oncol; 2019; 9():1047. PubMed ID: 31681585
    [No Abstract]   [Full Text] [Related]  

  • 27. Association of Metabolic Syndrome With Risk of Lung Cancer: A Population-Based Prospective Cohort Study.
    Li M; Cao SM; Dimou N; Wu L; Li JB; Yang J
    Chest; 2024 Jan; 165(1):213-223. PubMed ID: 37572975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic syndrome and rare gynecological cancers in the metabolic syndrome and cancer project (Me-Can).
    Nagel G; Concin H; Bjørge T; Rapp K; Manjer J; Hallmans G; Diem G; Häggström C; Engeland A; Almquist M; Jonsson H; Selmer R; Stocks T; Tretli S; Ulmer H; Stattin P; Lukanova A
    Ann Oncol; 2011 Jun; 22(6):1339-1345. PubMed ID: 20966183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes.
    Grundmark B; Garmo H; Loda M; Busch C; Holmberg L; Zethelius B
    Cancer Epidemiol Biomarkers Prev; 2010 Aug; 19(8):2088-96. PubMed ID: 20647401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of metabolic syndrome over 9 years follow-up; the importance of sex differences in the role of insulin resistance and other risk factors.
    Hadaegh F; Hasheminia M; Lotfaliany M; Mohebi R; Azizi F; Tohidi M
    PLoS One; 2013; 8(9):e76304. PubMed ID: 24086723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The association between metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study in China.
    Xu S; Zhang GM; Guan FJ; Dong DH; Luo L; Li B; Ma XC; Zhao J; Sun LJ
    World J Surg Oncol; 2015 Aug; 13():236. PubMed ID: 26246367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance.
    Colicchia M; Morlacco A; Rangel LJ; Carlson RE; Dal Moro F; Karnes RJ
    Eur Urol Focus; 2019 May; 5(3):425-432. PubMed ID: 29306730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between cannabis use with urological cancers: A population-based cohort study and a mendelian randomization study in the UK biobank.
    Huang J; Huang D; Ruan X; Huang J; Xu D; Heavey S; Olivier J; Na R
    Cancer Med; 2023 Feb; 12(3):3468-3476. PubMed ID: 35975633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SGLT2 inhibition and three urological cancers: Up-to-date results.
    Lin L; Ning K; Xiang L; Peng L; Li X
    Diabetes Metab Res Rev; 2024 Mar; 40(3):e3797. PubMed ID: 38523292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic syndrome and its component traits present gender-specific association with liver cancer risk: a prospective cohort study.
    Xia B; Peng J; Enrico T; Lu K; Cheung EC; Kuo Z; He Q; Tang Y; Liu A; Fan D; Zhang C; He Y; Pan Y; Yuan J
    BMC Cancer; 2021 Oct; 21(1):1084. PubMed ID: 34620113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Impact of Metformin Use with Survival Outcomes in Urologic Cancers: A Systematic Review and Meta-Analysis.
    Yao X; Liu H; Xu H
    Biomed Res Int; 2021; 2021():5311828. PubMed ID: 34660791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of urinary tract cancers following kidney or ureter stones.
    Chow WH; Lindblad P; Gridley G; Nyrén O; McLaughlin JK; Linet MS; Pennello GA; Adami HO; Fraumeni JF
    J Natl Cancer Inst; 1997 Oct; 89(19):1453-7. PubMed ID: 9326915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low serum 25-hydroxyvitamin D is associated with increased risk of the development of the metabolic syndrome at five years: results from a national, population-based prospective study (The Australian Diabetes, Obesity and Lifestyle Study: AusDiab).
    Gagnon C; Lu ZX; Magliano DJ; Dunstan DW; Shaw JE; Zimmet PZ; Sikaris K; Ebeling PR; Daly RM
    J Clin Endocrinol Metab; 2012 Jun; 97(6):1953-61. PubMed ID: 22442263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benign Prostatic Hyperplasia and the Risk of Prostate Cancer and Bladder Cancer: A Meta-Analysis of Observational Studies.
    Dai X; Fang X; Ma Y; Xianyu J
    Medicine (Baltimore); 2016 May; 95(18):e3493. PubMed ID: 27149447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The metabolic syndrome and cancer: Is the metabolic syndrome useful for predicting cancer risk above and beyond its individual components?
    Harding J; Sooriyakumaran M; Anstey KJ; Adams R; Balkau B; Briffa T; Davis TM; Davis WA; Dobson A; Giles GG; Grant J; Knuiman M; Luszcz M; Mitchell P; Pasco JA; Reid C; Simmons D; Simons L; Tonkin A; Woodward M; Shaw JE; Magliano DJ
    Diabetes Metab; 2015 Dec; 41(6):463-9. PubMed ID: 26037090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.